For several years, policy-makers and commentators have expressed concern about the resilience of the United States’ pharmaceutical supply chain. Current U.S.-based manufacturing capabilities have been at the forefront of...more
10/8/2021
/ Biden Administration ,
Biomedical Advanced Research and Development Authority (BARDA) ,
China ,
Competition ,
Coronavirus/COVID-19 ,
Defense Production Act ,
Department of Defense (DOD) ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Manufacturers ,
NDAA ,
Pharmaceutical Industry ,
Supply Chain
As has been widely reported, earlier this summer, President Biden issued Executive Order (EO) 14036, “Promoting Competition in the American Economy.” The EO provides insight into how the Biden-Harris administration plans to...more
9/10/2021
/ Biden Administration ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
CMMI ,
Competition ,
Department of Health and Human Services (HHS) ,
Executive Orders ,
Federal Trade Commission (FTC) ,
Healthcare Reform ,
Hospitals ,
Life Sciences ,
Pharmaceutical Industry
In this new episode of OnAir: Health Care, Akin Gump health care senior policy advisor Matthew Hittle and consultant Dr. Mario Ramirez welcome Akin Gump public law and policy partner Clete Willems and Centrient...more
8/5/2021
/ Biden Administration ,
Coronavirus/COVID-19 ,
Intellectual Property Protection ,
Manufacturers ,
Onshoring ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs ,
Supply Chain ,
Trade Secrets ,
TRIPS Agreement ,
Vaccinations ,
Waivers ,
WTO
In this new episode of OnAir: Health Care, Akin Gump health care senior policy advisor Matthew Hittle and consultant Dr. Mario Ramirez welcome public law and policy partners Ed Pagano and Clete Willems to talk federal health...more
4/16/2021
/ American Rescue Plan Act of 2021 ,
Biden Administration ,
Budget Reconciliation ,
Centers for Disease Control and Prevention (CDC) ,
Coronavirus/COVID-19 ,
Health Care Providers ,
Hospitals ,
Infectious Diseases ,
Infrastructure ,
Intellectual Property Protection ,
Legislative Agendas ,
New Guidance ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Physicians ,
Public Health ,
Public Policy ,
Vaccinations